Eucker J, Possinger K
Medizinische Klinik mit Schwerpunkt Onkologie und Hämatologie, Charité - Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, 10117 Berlin.
Dtsch Med Wochenschr. 2011 Mar;136(10):486-91. doi: 10.1055/s-0031-1274532. Epub 2011 Mar 1.
Breast cancer is the most frequent tumor in women. Clinical research over the last few years has resulted in an increasing differentiation of treatment strategies in the adjuvant setting as well as in metastatic breast cancer. In recent years, the medical treatment of breast cancer was complemented by agents with new mechanisms of action that depend on biological properties of the tumor. As these agents target tumor specific characteristics they are called targeted agents or targeted therapy. Most frequently, different receptors, key proteins of intracellular pathways, thyrosinkinases, or cytokines serve as tumor targets. Even in endocrine treatment relevant changes of practical guidelines emerged. The most important targeted therapies are reviewed with special regard to metastatic breast cancer.
乳腺癌是女性中最常见的肿瘤。过去几年的临床研究使得辅助治疗以及转移性乳腺癌的治疗策略日益分化。近年来，乳腺癌的药物治疗得到了具有新作用机制的药物的补充，这些药物依赖于肿瘤的生物学特性。由于这些药物靶向肿瘤的特定特征，它们被称为靶向药物或靶向治疗。最常见的是，不同的受体、细胞内信号通路的关键蛋白、酪氨酸激酶或细胞因子作为肿瘤靶点。甚至在内分泌治疗方面，实用指南也出现了相关变化。本文将特别针对转移性乳腺癌对最重要的靶向治疗进行综述。
